AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$SLS

SLS Stock Surges After-Hours: Sellas Says 'Transformative' Phase 3 AML Results Are Coming This Month

Sellas (SLS) stock rose after-hours following news of upcoming Phase 3 AML trial results. The Phase 2 study showed 34% response rate, with higher efficacy in specific subtypes. Sellas has $134.7M in cash, with Q3 net loss widening to $10.1M. The company plans to study SLS009 in pancreatic cancer. Retail sentiment improved to 'neutral'. SLS stock is up 113% year-to-date.

Original reporting
finance.yahoo.com
Published Nov 13, 2026, 1:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
SLS Stock Surges After-Hours: Sellas Says 'Transformative' Phase 3 AML Results Are Coming This Month — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$SLSBullishMed
01

Why it matters

The Phase 2 results provide a catalyst that could move the stock ahead of the ASH meeting.

02

Market read

New trial data creates immediate trading interest for SLS, with potential upside before the ASH conference.

03

What to watch

Potential cash burn and need for additional funding may limit upside.

Relevance 8/10Novelty 8/10Timing: after-hours today

Background

Sellas Life Sciences is a micro‑cap biotech focused on AML therapies; the company recently disclosed cash balances and Q3 loss.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

Sellas reported Phase 2 AML trial results with 34% overall response and up to 54% in monocytic AML, a fresh data point not previously disclosed.

Expected impact

likely upside as market prices in the encouraging trial outcomes

Evidence & confidence

The trial shows meaningful response rates and survival signals, prompting speculative buying ahead of the ASH presentation.

Market effects

Sector

Positive AML data could lift other biotech stocks developing similar therapies.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Modest, as AML trial results are of niche interest.

Counterpoint

What could challenge this read

If the data does not translate into regulatory approval, the rally could be short-lived.

Key entities

  • Company
    Sellas Life Sciences Inc.

    Biotech developing AML treatments.

Read at source← All news

Related articles

$SLSMed

SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update - Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patien

SEC EDGAR 8-K
$SLSMedAI 8/10

SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas

Sellas Life Sciences (SLS) stock rose 0.4% overnight after Citigroup cut its stake by 64%, while retail investors highlighted the potential value of SLS009. SLS009 showed 34% response rate in a Phase 2 AML study, with higher rates in specific subtypes. Sellas also expects Phase 2 and Phase 3 trial results this quarter. SLS stock is up 142% year-to-date.

stocktwits.com
$INTCHighAI 8/10

Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In Focus

Intel (INTC) reported Q3 sales of $16.5B, up 21% YoY, and beat earnings estimates. Weak PC demand due to memory semiconductor shortages impacted results. AMZN's earnings also dragged down chipmakers like NVDA, MU, AVGO, and AMD. U.S. consumer spending rose in September with inflation at 3.6%. Geopolitical tensions in the Strait of Hormuz pushed oil prices higher. IOVA and SLS also saw significant share price declines.

finance.yahoo.com
$SLSMedAI 8/10

SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?

Sellas Life Sciences (SLS) announced its Phase 3 Regal trial for Galinpepimut-S reached 80 events, triggering final analysis. Preliminary results are expected this quarter, but no survival benefits have been disclosed. SLS stock fell 15% to $10.38, despite retail investors expressing bullish sentiment. The company also anticipates Q4 data from its Phase 2 SLS009 study in newly diagnosed AML.

finance.yahoo.com